Research Analysts Set Expectations for Danaher Co.’s FY2024 Earnings (NYSE:DHR)

Danaher Co. (NYSE:DHR) – Equities research analysts at William Blair upped their FY2024 earnings per share estimates for shares of Danaher in a research report issued on Wednesday, April 24th. William Blair analyst M. Larew now anticipates that the conglomerate will post earnings per share of $7.67 for the year, up from their prior estimate of $7.61. The consensus estimate for Danaher’s current full-year earnings is $7.65 per share.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm’s quarterly revenue was down 2.6% on a year-over-year basis. During the same period last year, the company posted $2.36 EPS.

Several other equities research analysts have also weighed in on DHR. Citigroup raised their price objective on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday. Royal Bank of Canada raised their price objective on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. TD Cowen raised their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Finally, Robert W. Baird raised their target price on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average target price of $269.64.

Danaher Stock Performance

DHR opened at $246.58 on Friday. The firm has a market cap of $182.64 billion, a PE ratio of 41.79, a P/E/G ratio of 3.78 and a beta of 0.83. The company has a quick ratio of 1.37, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The business has a fifty day simple moving average of $248.87 and a 200-day simple moving average of $231.16. Danaher has a fifty-two week low of $182.09 and a fifty-two week high of $259.00.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. This is a positive change from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date was Wednesday, March 27th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the transaction, the senior vice president now directly owns 29,830 shares in the company, valued at $7,457,798.30. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 2,622 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the transaction, the senior vice president now owns 4,244 shares in the company, valued at $1,029,891.48. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 106,565 shares of company stock worth $26,641,364. Corporate insiders own 11.10% of the company’s stock.

Hedge Funds Weigh In On Danaher

Several institutional investors have recently bought and sold shares of the stock. ST Germain D J Co. Inc. boosted its stake in shares of Danaher by 1.4% during the 1st quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock worth $719,000 after buying an additional 41 shares during the last quarter. Godsey & Gibb Inc. raised its holdings in shares of Danaher by 3.0% in the 1st quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock valued at $360,000 after purchasing an additional 42 shares during the period. Nicholas Hoffman & Company LLC. raised its holdings in shares of Danaher by 2.3% in the 4th quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after purchasing an additional 43 shares during the period. Los Angeles Capital Management LLC raised its holdings in shares of Danaher by 1.3% in the 4th quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock valued at $803,000 after purchasing an additional 43 shares during the period. Finally, Berger Financial Group Inc raised its holdings in shares of Danaher by 1.7% in the 4th quarter. Berger Financial Group Inc now owns 2,517 shares of the conglomerate’s stock valued at $582,000 after purchasing an additional 43 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.